UK markets closed

Edwards Lifesciences Corporation (EW)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
87.98+0.52 (+0.59%)
At close: 04:00PM EDT
87.98 0.00 (0.00%)
After hours: 04:39PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 53.02B
Enterprise value 52.02B
Trailing P/E 37.92
Forward P/E 32.47
PEG ratio (5-yr expected) 3.59
Price/sales (ttm)8.70
Price/book (mrq)7.45
Enterprise value/revenue 8.47
Enterprise value/EBITDA 29.41

Trading information

Stock price history

Beta (5Y monthly) 1.10
52-week change 38.07%
S&P500 52-week change 326.14%
52-week high 396.12
52-week low 360.57
50-day moving average 389.61
200-day moving average 378.71

Share statistics

Avg vol (3-month) 33.21M
Avg vol (10-day) 32.28M
Shares outstanding 5602.6M
Implied shares outstanding 6621.55M
Float 8596.58M
% held by insiders 10.89%
% held by institutions 184.75%
Shares short (30 Apr 2024) 49.63M
Short ratio (30 Apr 2024) 43.06
Short % of float (30 Apr 2024) 41.61%
Short % of shares outstanding (30 Apr 2024) 41.60%
Shares short (prior month 28 Mar 2024) 410.38M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 23:1
Last split date 301 Jun 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 23.01%
Operating margin (ttm)27.39%

Management effectiveness

Return on assets (ttm)12.05%
Return on equity (ttm)21.28%

Income statement

Revenue (ttm)6.14B
Revenue per share (ttm)10.15
Quarterly revenue growth (yoy)9.50%
Gross profit (ttm)N/A
EBITDA 1.92B
Net income avi to common (ttm)1.41B
Diluted EPS (ttm)2.32
Quarterly earnings growth (yoy)3.30%

Balance sheet

Total cash (mrq)1.7B
Total cash per share (mrq)2.82
Total debt (mrq)699.2M
Total debt/equity (mrq)9.73%
Current ratio (mrq)3.76
Book value per share (mrq)11.82

Cash flow statement

Operating cash flow (ttm)528.2M
Levered free cash flow (ttm)671.94M